Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Tesomet in Hypothalamic Obesity
2021-000146-18Phase 2Terminated
- Sponsor
- Saniona
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypothalamic obesity (HO), pituitary diseases and disorder of nutritional metabolism comparing Tesomet with Placebo (2 arms). Primary endpoint: Change in body weight from baseline to Week 36. Started Nov 2021; status: terminated.
02
Drugs
Tesomet
03
Conditions
hypothalamic obesity (HO)pituitary diseasesdisorder of nutritional metabolism
Beyond the preview
Go deeper on 2021-000146-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000146-18.